CompletedPhase 2NCT01499121
Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
Studying Clear cell renal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sunnybrook Health Sciences Centre
- Principal Investigator
- Georg A. Bjarnason, MDSunnybrook Health Sciences Centre
- Intervention
- Sunitinib(drug)
- Enrollment
- 117 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2017
Study locations (13)
- Tom Baker Cancer Centre, Calgary, Alberta, Canada
- Cross Cancer Institute, Edmonton, Alberta, Canada
- BC Cancer Agency - Vancouver, Vancouver, British Columbia, Canada
- CancerCare Manitoba, Winnipeg, Manitoba, Canada
- QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
- Juravinski Cancer Centre, Hamilton, Ontario, Canada
- Kingston General Hospital Research Institute, Kingston, Ontario, Canada
- London Health Sciences Centre, London, Ontario, Canada
- Durham Regional Cancer Centre, Oshawa, Ontario, Canada
- Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Princess Margaret Hospital, Toronto, Ontario, Canada
- Notre-Dame Hospital, Montreal, Quebec, Canada
Collaborators
Pfizer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01499121 on ClinicalTrials.govOther trials for Clear cell renal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07128680Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerCity of Hope Medical Center
- RECRUITINGPHASE2NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCKarie Runcie
- RECRUITINGPHASE2NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)Brian Rini
- RECRUITINGPHASE2NCT07469683An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaYonsei University
- RECRUITINGPHASE1, PHASE2NCT07227415A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPfizer
- RECRUITINGPHASE1, PHASE2NCT07551349Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaBeijing Biotech
- RECRUITINGPHASE2NCT07223541Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaUniversity of Oklahoma